Next-Gen Proteomics for Translational and Clinical Research

Next-Gen Proteomics for Translational and Clinical Research

Join us for an evening of scientific exchange around the use of Next-Gen Proteomics for translational and clinical research at the Botanic Gardens at the University of Utrecht. ​

Explore compelling success stories from our collaborators VectorY Therapeutics and Gustave Roussy Institute. Engage in networking sessions for in-depth discussions around the use of Proteomics with our scientific community in Utrecht. ​

This is a unique opportunity to connect and delve into the forefront of scientific innovation. We look forward to your participation!​

 

Time & Location

 

Wednesday, March 26
5 PM – 7 PM (CET)

 

University of Utrecht​ Botanic Gardens​ (Room: Serre​)
Budapestlaan 17
3584 CD, Utrecht
Netherlands

 

 

 

5.00 – 5.20 PM      Welcome Drinks & Networking

5.20 – 5.30 PM      Welcome Presentation: Biognosys

5.30 – 6.00 PM      Exploring the Tumor Microenvironment in Patients with MMRd Endometrial Cancer Undergoing Immune Checkpoint Inhibitor Therapy: Proteomic Insights into Immune Resistance Mechanisms

6.00 – 6.30 PM      Untargeted LC-MS Applied to ALS iMNs Allows an Insight into the Disease Model and Provides an Insight into Intracellular AAV Effects

6.30 – 7.00 PM      Mixer & Networking

Scientific Program

Juan Francisco Grau, MD, obtained his medical degree from the University of Seville (2007–2013) before completing his Medical Oncology Residency at Vall d’Hebron University Hospital in Barcelona (2014–2019). He then pursued training as a clinical fellow in the Gynecologic Cancer Unit at Vall d’Hebron Hospital under the mentorship of Dr. Ana Oaknin, gaining extensive experience in clinical research and the conduct of clinical trials.

In 2023, Dr. Grau completed a two-year Translational Research Fellowship in the Gynecological Cancer Research Laboratory at Gustave Roussy Institute in Villejuif, France, under the guidance of Dr. Alexandra Leary. His research during this fellowship focused on the immunoprofiling of gynecological cancers.

Starting in January 2025, he will also be pursuing a PhD at the University of Paris-Saclay – Gustave Roussy Institute, with a project focused on analyzing the tumor microenvironment in mismatch repair-deficient endometrial cancer to optimize the prediction of resistance to immune checkpoint inhibitors and explore strategies to overcome it.

Rob Haselberg, Ph.D. is Head Translational Biomarkers at VectorY Therapeutics. His work focuses on the development and application of assays needed in support of both the preclinical and clinical development of VectorY’s vectorized antibody treatments. Besides that, he is the subject matter expert on LC-MS, supporting mechanism-of-action studies and therapeutic drug monitoring activities.

Contact

    Close banner

    New: Spectronaut® 19

    Unlock Your Data's True Story

    New: Spectronaut® 19

    Unlock Your Data's True Story

    Learn More